Literature DB >> 29277687

Defibrillator shocks and their effect on objective and subjective patient outcomes: Results of the PainFree SST clinical trial.

Samuel F Sears1, Lindsey Rosman2, Shingo Sasaki3, Yusuke Kondo4, Laurence D Sterns5, Edward J Schloss6, Takashi Kurita7, Albert Meijer8, Judith Raijmakers9, Bart Gerritse9, Angelo Auricchio10.   

Abstract

BACKGROUND: The effect of implantable cardioverter-defibrillator (ICD) shock on device-measured activity and patient-reported outcomes is unknown.
OBJECTIVE: The purpose of this study was to analyze the acute and long-term effects of ICD shock on objective behavioral data (ie, device-based physical activity) and subjective patient-reported outcomes (eg, quality of life and shock anxiety).
METHODS: The PainFree Smart Shock Technology (SST) clinical trial included 2770 patients with a single- or dual-chamber ICD or cardiac resynchronization therapy - defibrillator device who were followed for 22 ± 9 months. Participants completed measures of quality of life (EuroQol-5D [EQ-5D] questionnaire) and shock anxiety (Florida Shock Anxiety Scale) at baseline, biannual visits, and monthly for 6 months after an ICD shock. Daily physical activity data were obtained from a built-in device accelerometer.
RESULTS: The average daily activity was 185.3 ± 119.4 min/d. Activity was significantly reduced after an ICD shock (P < .0001) and recovered to a normal level after ∼90 days. An ICD shock was also associated with decreased quality of life (EQ5-D health score) and increased EQ-5D anxiety scores, but it did not affect mobility, self-care, activity, or pain. Similarly, shock anxiety (Florida Shock Anxiety Scale) increased in shocked patients and remained significantly elevated at 24 months, regardless of appropriate or inappropriate shock delivery.
CONCLUSION: ICD shocks have a long-lasting adverse effect on both objective, device-measured physical activity and subjective patient-reported outcomes of quality of life and shock anxiety. Successful management of patients with an ICD requires attention to clinically relevant behavioral and psychological outcomes to expedite recovery and return to activities of daily living.
Copyright © 2017 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Accelerometer; ICD; Patient activity; Quality of life; Shock anxiety

Mesh:

Year:  2017        PMID: 29277687     DOI: 10.1016/j.hrthm.2017.12.026

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  14 in total

1.  Phase I/II Trial of Electrophysiology-Guided Noninvasive Cardiac Radioablation for Ventricular Tachycardia.

Authors:  Clifford G Robinson; Pamela P Samson; Kaitlin M S Moore; Geoffrey D Hugo; Nels Knutson; Sasa Mutic; S Murty Goddu; Adam Lang; Daniel H Cooper; Mitchell Faddis; Amit Noheria; Timothy W Smith; Pamela K Woodard; Robert J Gropler; Dennis E Hallahan; Yoram Rudy; Phillip S Cuculich
Journal:  Circulation       Date:  2019-01-15       Impact factor: 29.690

2.  Body Image and Adjustment among Patients with Heart Rhythm Management Devices following Cardiac Rehabilitation Program: A Randomized, Controlled Clinical Trial.

Authors:  Mahnaz Rakhshan; Zeinab Khoshnood; Leila Ansari; Amir Aslani
Journal:  Clin Med Res       Date:  2022-01-07

3.  Survival After Implantable Cardioverter-Defibrillator Shocks.

Authors:  Mehmet K Aktaş; Arwa Younis; Wojciech Zareba; Valentina Kutyifa; Helmut Klein; James P Daubert; Mark Estes; Scott McNitt; Bronislava Polonsky; Ilan Goldenberg
Journal:  J Am Coll Cardiol       Date:  2021-05-25       Impact factor: 27.203

4.  Prognostic Importance of Defibrillator-Appropriate Shocks and Antitachycardia Pacing in Patients With Mild Heart Failure.

Authors:  Yitschak Biton; Usama A Daimee; Jayson R Baman; Valentina Kutyifa; Scott McNitt; Bronislava Polonsky; Wojciech Zareba; Ilan Goldenberg
Journal:  J Am Heart Assoc       Date:  2019-03-19       Impact factor: 5.501

Review 5.  Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy.

Authors:  M Akhtar; P M Elliott
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

6.  Current clinical practice of cardiac resynchronization therapy in Turkey: Reflections from Cardiac Resynchronization Therapy Survey-II.

Authors:  Duygu Koçyiğit; Nedim Umutay Sarıgül; Ali Timuçin Altın; Serkan Çay; Veli Polat; Serkan Saygı; Hasan Ali Gümrükçüoğlu; Kani Gemici; Barış İkitimur; Ahmet Akyol; Ahmet Kaya Bilge; İbrahim Başarıcı; Emin Evren Özcan; Mesut Demir; Hasan Kutsi Kabul; Ender Ornek; Camilla Normand; Cecilia Linde; Kenneth Dickstein
Journal:  Anatol J Cardiol       Date:  2020-12       Impact factor: 1.596

7.  Risk factors for the first and second inappropriate implantable cardioverter-defibrillator therapy.

Authors:  Nobuhiro Nishii; Takashi Noda; Takashi Nitta; Yoshifusa Aizawa; Tohru Ohe; Takashi Kurita
Journal:  Int J Cardiol Heart Vasc       Date:  2021-04-26

8.  Psychosocial symptoms of ventricular arrhythmias: Integrating patient-reported outcomes into clinical care.

Authors:  Uday Sandhu; Adrienne H Kovacs; Babak Nazer
Journal:  Heart Rhythm O2       Date:  2021-12-17

9.  Measuring Physical Activity With Implanted Cardiac Devices: A Systematic Review.

Authors:  Lindsey Rosman; Rachel Lampert; Samuel F Sears; Matthew M Burg
Journal:  J Am Heart Assoc       Date:  2018-05-17       Impact factor: 5.501

10.  Implantable cardioverter defibrillator therapy is cost effective for primary prevention patients in Taiwan: An analysis from the Improve SCA trial.

Authors:  Reece Holbrook; Lucas Higuera; Kael Wherry; Dave Phay; Yu-Cheng Hsieh; Kuo-Hung Lin; Yen-Bin Liu
Journal:  PLoS One       Date:  2020-11-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.